Corrigendum: A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2023-09-04 DOI:10.1002/cmdc.202300455

引用次数: 0

Abstract

The first two lines of the final sentence in the abstract should read: “The triple blocker compound is as long as rimantadine, but can bind and block the V27A M2 channel…” (where ‘can’ replaces ‘could’). In addition, the first two sentences of the final paragraph on page 9 should read: “Using MAS ssNMR we probed the binding of compound 61 to V27 and L26F M2 using M2(18–60) (M2CD). Compared to very broad peaks in the apo-proteins spectra of both V27 and L26F, upon addition of the drug, a notable enhancement in peak resolution was observed, suggesting that the conformational freedom of the protein was reduced upon drug–protein complex formation with compound 61 (Figures 2 and 3).”

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

更正：一项关于金刚烷胺对突变型甲型流感M2通道活性的研究确定了一种多环笼胺三阻断剂，通过分子动力学模拟和固态NMR进行了探索。

摘要最后一句的前两行应该是:“三阻断剂化合物与金刚乙胺一样长，但可以结合并阻断V27A M2通道……”(此处用can代替could)。此外，第9页最后一段的前两句应该是:“使用MAS ssNMR，我们使用M2(18-60) (M2CD)探测了化合物61与V27和L26F M2的结合。与V27和L26F的载脂蛋白光谱中非常宽的峰相比，添加该药物后，观察到峰分辨率的显着增强，这表明在与化合物61形成药物-蛋白质复合物后，蛋白质的构象自由度降低了(图2和3)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.